The physiologic roles of Notch1 and Notch2 have been clarified in mouse models, particularly in the lymphoid system. Notch1 is preferentially expressed in immature T cells and is essential for specification of early hematopoietic progenitors toward the T-cell fate and for early T-cell development in the thymus 4 . In contrast, Notch2 is preferentially expressed in mature B cells and is required for the generation of a mature B-cell subset, known as splenic marginal zone B (MZB) cells in mice 5 . Notch1 was originally identified as a transforming gene in human T-cell acute lymphoblastic leukemia (T-ALL) cells harboring the t(7;9)(q34;q34) chromosomal translocation 6 . The N-terminal truncated form of Notch1 expressed in this type of T-ALL cell can induce the development of T-ALL when expressed in bone marrow cells that are then transplanted into recipient mice 7 . Importantly, more than 50% of childhood and 30% to 40% of adult human T-ALL cases carry Notch1 mutations that 5 lead to deregulated activation of Notch signaling [8] [9] [10] [11] , indicating that accelerated Notch signaling contributes to the development of human neoplasms.
Two regions of the Notch1 gene are major targets of oncogenic mutations in T-ALL.
Missense, insertion, and deletion mutations in the heterodimerization domains are thought to decrease the stability of the dimer, consisting of the extracellular and transmembrane subunits, which results in the progression of Notch1 cleavage without ligand stimulation 8, 12 . The other series of mutations accumulate in the PEST domain and its N-terminally flanking transactivation domain. All these mutations cause partial or complete deletion of the PEST domain, which are considered to result in the prolonged half-life of Notch1 ICN, because the PEST domain is responsible for polyubiquitylation-based degradation of ICN 13 .
These lines of information about Notch genes led us to examine the possibility that deregulation of Notch2 signaling is involved in the development of mature B-cell lymphomas.
We screened Notch2 gene mutations at the heterodimerization and PEST domains in 109 B-cell lymphoma samples, and found mutations in 5 samples, all of which were diffuse large B-cell lymphomas (DLBCL). Interestingly, two of the five samples had an increased copy number of the mutated Notch2 allele, and in another sample of the five the total copy number of the Notch2 allele was increased. Furthermore, we confirmed that the mutation-carrying Notch2 receptors had increased activity when stimulated by a ligand in vitro. We postulate that gain-of-function mutations of Notch2 are involved in the pathogenesis of a subset of DLBCL.
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Materials and methods
Patient materials and genomic DNA preparation. Patients (n=109) with various B cell lymphomas were enrolled in the study after informed consent was obtained. The study design was approved by the ethics committees of the University of Tokyo and Aichi Cancer Center.
Genomic DNA was extracted from cryopreserved samples using a commercial kit (PUREGENE TM , Gentra, Minneapolis, MN).
PCR-single-strand conformation polymorphism (SSCP). Based on the information of
Notch1 mutations in T-ALL and the high similarity between Notch1 and Notch2 genes, we confined our mutation analysis to exons 26, 27, and 35 of Notch2 that correspond to the heterodimerization domains (exons 26 and 27) and the C-terminal region containing the transactivation and PEST domains (exon 34), respectively. Oligonucleotide primers designed to amplify whole exon 26 and exon 27, and five divided portions of exon 35 are listed in Supplemental Table 1. The   32 P-labled PCR product was subjected to SSCP analysis as described in the literature 14 . In brief, the PCR mixture was heated at 80ºC and applied to 5% polyacrylamide gel containing 10% glycerol. After 2 -4 h electrophoresis with cooling, the gel was dried on filter paper and exposed to X-ray film. The PCR products were directly sequenced or bands with aberrant migration were excised from the gel and subjected to direct sequencing when indicated.
High-density oligonucleotide microarray analysis. Genome-wide copy number detection analysis was performed as described previously 15 . In brief, Affimetrix GeneChip Mapping 100 k high-density oligonucleotide arrays (Affimetrix, Inc, Santa Clara, CA) were used and the data were analyzed using the CNAG algorithm. Plasmid preparation. In the human full-length Notch2 cDNA (wtN2) (a gift from S.
Artavanis-Tsakonas, Harvard University), the stop codon corresponding to the nonsense mutation (7454 C/T), the single-base deletion mutation corresponding to 7120Del, and the point mutation corresponding to 7614 G/A were introduced. Mutant primers were used for PCR and the resulting products were sequenced and used to replace the corresponding 8 fragment of wtN2 cDNA to create the Notch2 with the nonsense mutation and the R2453Q mutation (nsmN2, delstN2, and rqN2, respectively). These cDNAs were inserted in pTracerCMV (Invitrogen, Carlsbad, CA)
Establishment of CHO(r) cells stably expressing wild-type and mutant human Notch2.
CHO(r) cells were transfected with pTracerCMV/wtN2, pTracerCMV/nsmN2, pTracerCMV/delstN2, and pTracerCMV/rqN2, and selected for zeocin (400 µg/ml) resistance.
The resulting zeocin-resistant cells were single-cell sorted using the anti-human Notch2 Western blot analysis. Immunoblotting was performed as described previously 17 . In brief, 1 Transcriptional activation assay. The luciferase assay was performed as described previously 17 . In brief, 2 x 10 5 CHO(r) cells expressing wtN2, Notch2 with truncatation at 2400 (nsmN2), Notch2 with truncation after 6 amino acids insertion at 2288 (delstN2), and 9
Notch2 with an R2453Q mutation (rqN2) were inoculoated in a 6-well dish and the next day transfected with the pGa981-6 luciferase reporter plasmid (2 µg) using the Superfect Five distinct nucleotide changes were detected in 11 of the 109 B-cell lymphoma samples, exclusively in exon 34. Whereas two of the five changes detected in 6 of the 11 samples were single nucleotide polymorphisms (SNP) without amino acid changes, the other 3 nucleotide changes detected in the remaining 5 samples (Fig. 1 A-E) were thought to represent somatic mutations resulting in premature truncation or single amino acid substitution (Table 1) . A nonsense mutation, C to T at nucleotide 7454 (based on the published human Notch2 sequence, NM_024408), in three cases (Fig. 1A-C ) and a single base deletion at position 7120 in another case (Fig. 1D ), led to premature truncation of the Notch2 protein (Table 1) . These Notch2 proteins lacked a part or the entire region of the PEST domain. The other single nucleotide change, G to A at 7614, resulted in the replacement of arginine with glutamine on the C-terminal side of the PEST domain ( Fig. 1E and Table 1 ). The G7614A change is not listed in the public SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/; as of October 23, 2007) . In addition, the dose of the mutant A allele was unbalanced relative to the wild-type G allele (Fig. 1E) , further decreasing the possibility of an SNP. Constitutive DNA was available in one case (W109539) 11 and was confirmed to be the wild-type sequence (Fig. 1F) , which definitely concluded that the mutation in the tumor was somatic origin.
Mutation-carrying cases show the same expression pattern of CD10, BCL6, and MUM-1. All five cases with Notch2 mutations were diagnosed as DLBCL, and were uniformly immunohistochemically negative for CD10 and positive for BCL6 and MUM-1 (Fig. 2) . We have reviewed 24 DLBCL subjects without Notch2 mutations for expression of (Fig. 3B) analyses. An allele-specific copy number detection analysis revealed an increase in the copy number of a single Notch2 allele (Fig. 3A, left panel) . This allele must correspond to the allele carrying the mutated Notch2 gene because the mutated band was overwhelmingly dominant in the PCR-SSCP analysis (Fig. 1A) . In the other sample (W121672) with a Notch2 copy number increase, the genomic region encompassing the Notch2 locus on chromosome 1p through the telomere of chromosome 1q had three copies, whereas most of the 1p region had only one copy (Fig. 3A, right panel). The Notch2 copy number increase was confirmed by a quantitative real-time PCR analysis (Fig. 3C ). We were unable to determine whether the third Notch2 allele contained wild-type or mutant Notch2 in this sample. In the third sample carrying the nonsense mutation (L8), a change in the Notch2 copy number was not detected in the microarray analysis (data not shown) and quantitative PCR analysis revealed that the copy number was normal (Fig. 3C ). Both Notch2 alleles in this sample, however, were likely to have the nonsense mutation, thus representing uniparental disomy, losing the wild-type Notch2, because the mutant band was overwhelmingly dominant in the PCR-SSCP analysis (Fig. 1C) . Taken together, these findings indicate that some DLBCL samples have Notch2 mutations and an increased copy number of the mutated Notch2 gene.
Notch2 receptors with mutations have increased activity in vitro.
To investigate the function of the Notch2 receptors encoded by mRNA with the nonsense mutation (nsmN2), the single-base deletion mutation (delst), and missense mutation (rqN2), we established CHO(r) cell lines 17 expressing wild-type Notch2, nsmN2, delstN2, and rqN2 [wtN2/CHO(r), nsmN2/CHO(r), delstN2/CHO(r), and rqN2/ CHO(r)] and obtained independent clones expressing each Notch2 protein at similar levels, using fluorescence-activated cell sorting with human Notch2-specific antibody ( Fig. 4A; Supplemental Fig. 1) . A Western blot analysis 13 demonstrated that the expected sizes of the transmembrane subunit species were expressed at comparable levels (Fig. 4B) . In a Notch-sensitive luciferase reporter assay 24 , the luciferase activity was significantly increased in nsmN2/CHO(r), delstN2/CHO(r), and rqN2/CHO(r) cells, compared with that in wtN2/CHO(r) cells when stimulated with Delta1-Fc. Basal luciferase activities with control IgG also tended to be higher in the three mutant Notch2-expressing CHO(r) cells lines than that in wtN2/CHO(r) (Fig. 4C) . These results indicated that all the three kinds of mutation-carrying Notch2 had significantly increased levels of transcriptional activity compared with wtN2, irrespective of the strength of the Delta1 stimulation.
To evaluate the effect of γ-secretase inhibitor on wtN2 and nsmN2, we added graded concentrations of DAPT to the Delta1-Fc-stimulated bulk wtN2/CHO(r) and nsmN2/CHO(r).
The elevated luciferase activity was reproducible with the bulk nsmN2/CHO(r), which was reduced by DAPT in a concentration-dependent manner (Fig. 4D) . The luciferase levels of both wtN2/CHO(r) and nsmN2/CHO(r) at 3 µM DAPT in the presence of Delta1-FC were below those in the presence of control IgG without DAPT, respectively, implying the spontaneous Notch2 activity with only IgG in the culture system. The results also indicate that the increased Notch2 activity by the PEST domain deletion is still dependent on the γ-secretase activity.
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Discussion
The The activity was also increased in the rqN2, which has the 2453R/Q single amino acid substitution. This amino acid is located on the C-terminal side of the PEST domain, and it is unknown whether this change affects the structure or function of the PEST domain.
Nevertheless, as the arginine residue is often a target of protein modification such as 15 methylation 25, 26 , this amino acid change might convey a significant alteration in the protein function and be involved in lymphomagenesis.
There are other examples of copy number increases associated with oncogenic gene alterations, such as double Philadelphia chromosomes (BCR/ABL copy number increase) in the blastic crisis of chronic myelogenous leukemia 27 and homozygous JAK2 mutations in polycythemia vera 22, 23 , both of which represent clonal evolution and selection. In the present study, we showed that at least two (or possibly three) cases had increased copy numbers of the mutated Notch2 allele due to gene amplification or mitotic recombination. This finding agrees with the recent understanding that the allelic copy number increases after an oncogenic mutation are a common mechanism of further transformation and selection of neoplastic cells.
Whether the presence of Notch2 gain-of-function mutations has a prognostic indicator or further define a clinical entity within DLBCL is yet to be clarified in future.
Although the number of cases are still smalll, our finding that all five cases with Notch2 mutations showed the same immunohistochemical staining pattern for CD10, BCL6, and MUM-1 might provide insight into this issue. DLBCL is highly heterogeneous clinically, morphologically, and genetically. The tissue microarray study based on immunostaining of the tissue samples identified three antigens (CD10, BCL6, and MUM-1) as useful markers to predict the results of mRNA expression array studies [28] [29] [30] , and the staining pattern of these three antigens could be used to divide DLBCL cases into germinal center B-cell-like (GCB) and non-GCB groups 21 . Whereas all the five cases carrying Notch2 mutations in our study 
